ProKidney Corp [NASDAQ: PROK] price plunged by -12.36 percent to reach at -$0.64.
A sum of 17530751 shares traded at recent session while its average daily volume was at 11.37M shares. ProKidney Corp shares reached a high of $5.45 and dropped to a low of $4.48 until finishing in the latest session at $4.54.
The one-year PROK stock forecast points to a potential upside of 1.3. The average equity rating for PROK stock is currently 2.29, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on ProKidney Corp [PROK]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PROK shares is $4.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PROK stock is a recommendation set at 2.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for ProKidney Corp shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on June 30, 2025. While these analysts kept the previous recommendation, JP Morgan raised their target price to Neutral. The new note on the price target was released on September 30, 2024, representing the official price target for ProKidney Corp stock. Previously, the target price had yet another raise to $6, while Guggenheim analysts kept a Buy rating on PROK stock.
PROK Stock Performance Analysis:
ProKidney Corp [PROK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 612.49. With this latest performance, PROK shares gained by 354.00% in over the last four-week period, additionally plugging by 148.09% over the last 6 months – not to mention a rise of 168.64% in the past year of trading.
Insight into ProKidney Corp Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and ProKidney Corp [PROK] shares currently have an operating margin of -58713.73% and a Gross Margin at -1497.39%. ProKidney Corp’s Net Margin is presently recorded at -22362.09%.
Return on Equity for this stock declined to -17.24%, with Return on Assets sitting at -17.24%.
PROK Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PROK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ProKidney Corp go to 2.98%.
ProKidney Corp [PROK] Institutonal Ownership Details
There are presently around $41.66%, or 59.55% of PROK stock, in the hands of institutional investors. The top three institutional holders of PROK stocks are: MORGAN STANLEY with ownership of 14.45 million shares, which is approximately 19.034%. SUVRETTA CAPITAL MANAGEMENT, LLC, holding 9.34 million shares of the stock with an approximate value of $$22.98 million in PROK stocks shares; and SUVRETTA CAPITAL MANAGEMENT, LLC, currently with $$9.78 million in PROK stock with ownership which is approximately 5.237%.
